Hefei Zhongren Technology
Implantable anticancer drugs for regional chemotherapy
About Hefei Zhongren Technology
Anhui Zhongren Technology Co., Ltd., established in 1996, is a pharmaceutical company based in Hefei, China, that specializes in the research, development, production, and sale of implantable anticancer drugs. The company is a leader in developing new implantable chemotherapeutic agents and is a key organizer of clinical research into new regional sustained-release chemotherapy methods. Its work primarily serves the domestic market.
The company's product pipeline includes sustained-release implants using drugs like doxorubicin and cisplatin. Anhui Zhongren Technology is actively engaged in clinical trials to evaluate the safety and efficacy of its products, such as using implantable sustained-release doxorubicin for liver cancer with a high risk of recurrence and implantable cisplatin for advanced liver cancer with portal vein tumor thrombus. These trials represent various stages of clinical research, from Phase 1 to Phase 3.
As of late 2008, Xu Jianjian was a significant shareholder in the company. In a notable 2016 transaction, the company agreed to acquire a 60% stake in Anhui Fengyuan Zhongren Pharmaceutical Co., Ltd. from Anhui Fengyuan Pharmaceutical Co., Ltd.
Source: Dealroom company dataNews
Open roles
Hefei Zhongren Technology in the Hefei ecosystem
The Hefei Zhongren Technology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Hefei Zhongren Technology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Hefei Zhongren Technology on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.